event-trade登录编辑
🏢 官网IRBWXTCodex · 实盘不做把握 8/10
北京时间·🕒 发布 04:05:00(美东 08-03 16:05)·⟳ 抓取 04:08:14 +3m14s·⚡ 决策 08-04 12:28:50 +8h20m·84.3 天前

BWXT拟以最高8亿美元出售医疗业务给Nordic Capital

交易本身偏正面:BWXT剥离医疗业务并保留少数股权,可把资本和管理资源集中到核国防与商用核电主业。

📄 原文BWXT↗ 原文
BWXT Selling Medical Business to Nordic Capital in Transaction Valued at up to $800 Million
BWXT will retain a minority ownership in the new company LYNCHBURG, Va. --(BUSINESS WIRE)--Aug. 3, 2026-- BWX Technolog…
不做 BWX Technologies(BWXT.US)
不做:同一具体催化已在2026-08-04 04:21 UTC被内部已处理消息库命中(“BWX Technologies拟最高8亿美元出售医疗业务给Nordic Capital”),本条为重复来源,不再生成交易卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗ ↗

关键理由

  • 交易本身偏正面:BWXT剥离医疗业务并保留少数股权,可把资本和管理资源集中到核国防与商用核电主业。
  • 最高8亿美元交易价值约为BWXT当前159亿美元市值的5.0%,有一定资产重估意义但不是新的未处理催化。
  • 查重命中同一具体事件,内部已在2026-08-04 04:21 UTC处理过“BWX Technologies拟最高8亿美元出售医疗业务给Nordic Capital”。

主要风险

  • 本条是同一催化的IR源/新闻源重复,不应再次推卡或重复生成交易指令。
  • 交易仍需监管审批并预计到2026年底才交割,短线主要是资产配置叙事而非即时现金流落地。
工具调用 · 历史记录,结果未知(3 种)
  • search_processed_events · 结果未知
  • stock_quote · 结果未知
  • kb_search · 结果未知

原文全文

展开原文 · 6,532 字
BWXT will retain a minority ownership in the new company
LYNCHBURG, Va.
--(BUSINESS WIRE)--Aug. 3, 2026--
BWX Technologies, Inc.
(NYSE: BWXT) announced today it has entered into a definitive agreement to sell its medical business to
Nordic Capital
, an experienced healthcare investor with broad expertise and a deep understanding of the radiopharmaceutical industry and its value chain. The transaction, valued at up to
$800 million
, includes BWXT Medical and Kinectrics’ stable medical isotopes business.
The sale will enable BWXT to concentrate resources and capital on accelerating growth in its core nuclear national security and commercial nuclear power markets, areas central to the company’s long-term strategy. Under Nordic Capital’s ownership, the medical business is expected to be well-positioned to scale, expand capabilities and advance its market presence in radiopharmaceuticals, including developing, manufacturing and delivering products for diagnostic imaging and radiotherapeutic treatments.
BWXT remains bullish on long-term growth in the radiopharmaceutical market and will maintain a meaningful minority ownership stake in the divested business. BWXT will also continue providing specialized isotope and radiochemical expertise under the agreement.
“Since acquiring the medical business in 2018, we have roughly tripled revenue, improved profitability and significantly expanded the product portfolio, including novel therapeutic isotopes,” said
Rex D. Geveden
, BWXT president and chief executive officer. “As the business enters its next phase, this transaction provides an opportunity for the medical team to grow under an owner deeply committed to the healthcare sector, as we concentrate management resources and capital on our core businesses in nuclear national security and nuclear power. We are very pleased to go forward as a minority partner to
Nordic Capital
in BWXT Medical’s future growth given the expertise and deep resources they bring to this business and the market.”
“We are excited about the next step as
Nordic Capital
sees significant potential to scale the business and expand access to cutting-edge radiopharmaceutical therapy," said
Christian Hedegaard
, partner,
Nordic Capital Advisors
. “Nordic Capital has a long track record of successful investments across both pharmaceuticals and life sciences, and radiopharmaceuticals sit squarely at the intersection of the two. That sector depth, combined with strong conviction in the BWXT Medical team’s capabilities, created a strong foundation for this partnership.”
The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026.
Solomon Partners
is serving as exclusive financial advisor to BWXT, and
Stikeman Elliott
is serving as legal counsel.
Kirkland & Ellis LLP
and McCarthy Tétrault are legal counsel for
Nordic Capital
.
Forward-Looking Statements
BWXT cautions that this release contains forward-looking statements, including, without limitation, statements relating to the anticipated benefits of the divestiture of its medical business. These forward-looking statements involve a number of risks and uncertainties, including, among other things, the timing and completion of the transaction; satisfaction of closing conditions and regulatory approvals; realization of anticipated transaction benefits; and potential business disruptions related to the transaction. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, please see BWXT’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.
About BWXT
At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven. A U.S.-based company with more than 11,000 employees, BWXT is a Fortune 1000 and Defense News Top 100 manufacturing and engineering innovator that provides safe and effective nuclear solutions for global security, clean energy, nuclear medicine, space exploration and environmental restoration. BWXT owns and operates 19 manufacturing facilities globally, and its 14 strategic partnerships support the U.S. and Canadian governments at more than two dozen additional locations.
For more information, visit
www.bwxt.com
. Follow us on
LinkedIn
,
X
,
Facebook
and
Instagram
.
About Nordic Capital
Nordic Capital is a leading international private equity investor and subsector specialist dedicated to building stronger, more resilient businesses through transformative, long-term growth in partnership with management teams. With over 35 years of experience, Nordic Capital currently manages approximately EUR 39 billion in assets, investing in middle-market companies across Northern Europe and North America. Rooted in its Nordic heritage and values, it combines global reach with local presence through dedicated sector investment advisory teams, bringing deep expertise across its core sectors: Healthcare, Technology & Payments, Financial Services, and Services & Industrial Tech. Through active ownership, strong operational capabilities, a global network of experts and technology-enabled transformation, Nordic Capital helps companies scale, innovate and become sustainable leaders. For more information, visit
www.nordiccapital.com
or connect on
LinkedIn
.
“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures, and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260803155801/en/
Media Contact
John Dobken
Senior Manager, Media & Public Relations
202.428.6913
jcdobken@bwxt.com
Investor Contact
Chase Jacobson
Vice President, Investor Relations
980.365.4300
investors@bwxt.com
Media Contact – Nordic Capital
Katarina Janerud
Communications Manager, Nordic Capital Advisors
+46 8 440 50 50
katarina.janerud@nordiccapital.com
Source: BWX Technologies, Inc.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。